Pharmacy Department Vice Chair Named

Contact: Louise DuPont

Photo of Russell J. Mumper
Russell J. Mumper

""

Since coming to UK in 1999, he has been principal investigator for more than $2.6 million in research grants. Mumper has more than 135 scientific publications and 20 patents or patents pending in the area of advanced drug delivery systems and nanotechnology. He serves on the editorial board of two pharmaceutical journals and has been a member of several scientific review panels for both the National Science Foundation and the National Institutes of Health.

""

LEXINGTON, Ky. (Nov. 9, 2004) -- The University of Kentucky College of Pharmacy appointed Russell J. Mumper vice chair of its Department of Pharmaceutical Sciences, effective Oct. 1.

The Department of Pharmaceutical Sciences includes faculty, staff, postdoctoral and graduate students engaged in a variety of pharmaceutical research topics ranging from studies of fundamental mechanisms of disease and drug action to new drug design and development. In addition to the support of basic research and graduate training missions in the pharmaceutical sciences, faculty play key roles in the economic development of Kentucky through their patents, development of UK intellectual property, and the Center for Pharmaceutical Science and Technology (CPST).

Mumper, an alumnus of the UK graduate program in pharmaceutical sciences, currently is associate professor and associate director of the CPST. Prior to coming to UK in 1999, he was director of product development at the ViroTex Corporation in The Woodlands, Texas, where he developed drug delivery systems and vaccines for skin and mucosal delivery. From 1994 to 1998, he was employed by Valentis (formerly GeneMedicine, Inc.), a non-viral gene therapy company in The Woodlands, Texas. From 1992 to 1994, he was a development scientist for Burroughs Wellcome Co. in Greenville, N.C.

Mumper’s research focuses primarily on the creation and investigation of novel drug delivery systems, including nanotemplate engineering of nano-based detection devices and cell-specific nanoparticles for tumor and brain targeting, gene therapy and vaccines.

Since coming to UK in 1999, he has been principal investigator for more than $2.6 million in research grants. Mumper has more than 135 scientific publications and 20 patents or patents pending in the area of advanced drug delivery systems and nanotechnology. He serves on the editorial board of two pharmaceutical journals and has been a member of several scientific review panels for both the National Science Foundation and the National Institutes of Health.

He received his doctorate in pharmaceutical sciences from UK in 1991 and a bachelor’s degree in chemistry from UK in 1988. Mumper also is a co-founder and chief scientific officer of NanoMed Pharmaceuticals Inc., an early-stage advanced drug delivery company.


Back to Campus News Homepage